| Business Summary | | DURECT
Corporation
is
engaged
in
the
treatment
of
chronic
diseases
and
conditions
by
developing
and
commercializing
pharmaceutical
systems
to
deliver
the
right
drug
to
the
right
place
in
the
right
amount
at
the
right
time.
The
Company's
pharmaceutical
systems
combine
engineering
innovations
and
delivery
technology
from
the
medical
device
and
drug
delivery
industries
with
its
proprietary
pharmaceutical
and
biotechnology
drug
formulations.
By
integrating
these
technologies,
the
Company
is
able
to
control
the
rate
and
duration
of
drug
administration,
as
well
as
target
the
delivery
of
the
drug
to
its
intended
site
of
action,
allowing
its
pharmaceutical
systems
to
meet
the
special
challenges
associated
with
treating
chronic
diseases
or
conditions.
Its
initial
portfolio
of
products
combines
the
DUROS
technology,
a
patented
drug
delivery
platform
licensed
for
specified
fields
of
use
from
ALZA
Corporation,
with
drugs
for
which
data
on
medical
efficacy
and
safety
are
available. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | DURECT
Corporation
is
involved
in
the
treatment
of
chronic
diseases
and
conditions
by
developing
and
commercializing
pharmaceutical
systems
to
deliver
the
right
drug
to
the
right
place
in
the
right
amount
at
the
right
time.
For
the
six
months
ended
6/01,
revenues
totalled
$3.1
million,
up
from
$1.1
million.
Net
loss
applicable
to
Com.
totalled
$25.9
million,
up
from
$9.9
million.
Results
reflect
the
acquisition
of
the
ALZET
product
line,
offset
by
increased
R&D
activity. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Felix Theeuwes, 63 Chairman,
CSO | $250K | James Brown, 44 Pres,
CEO, Director | 225K | Thomas Schreck, 43 CFO,
Director | 200K | Jean Liu, 32 VP,
Legal Gen. Counsel | -- | Dennis Fisher, M.D. VP,
Medical Affairs | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|